Ben Doranz, recipient of the 2024 Frank Baldino Bioscience CEO of the Year Award, joins Chris and Rachael this episode to discuss how he led his team through a transformative year in 2024. Under Ben's leadership, Integral Molecular secured an $8 million contract from NIAID to combat emerging viruses, as well as $2.7 million award to advance the Membrane Proteome Array for FDA qualifications as a drug development tool. If that wasn't enough, Ben also discussed the launch of Cell Surface Bio, a transformative antibody startup that will position itself as a key plater in the antibody reagent market. Hear how his vision will transform the industry, and how he takes steps to give back to the Philadelphia and PA life sciences community. 

Ver todos los episodios